Heptares grants Shire option on lead discovery programme
This article was originally published in Scrip
Executive Summary
Heptares Therapeutics has signed an exclusive option agreement with Shire Pharmaceuticals for its lead internal drug discovery programme, a novel adenosine A2A antagonist currently in preclinical development with potential for treating symptoms of Parkinson's disease and which may offer benefits in additional CNS diseases.